The Winship Cancer Institute of Emory University (Winship) was awarded a type I Cancer Center Support Grant (CCSG) in April 2009. This application represents the first competitive renewal seeking support for years 4-9. Winship is a research university-based matrix cancer center with a vision to be a transformative leader in integrating cancer research care. The 152 Winship members are actively engaged in one of four research programs: Cancer Genetics and Epigenetics, Cancer Cell Biology, Discovery and Developmental Therapeutics, and Cancer Prevention and Control. Winship's members are supported by five shared resources: Cell Imaging and Microscopy, Cancer Genomics, Biostatistics and Bioinformatics, Cancer Tissue and Pathology, and the Clinical Trials Office. Winship currently occupies more than 482k sq. ft. (sf) of dedicated clinical, research, and shared resource space under the direct control of the Executive Director, Walter J. Curran, Jr. M.D. Dr. Curran assumed this position in Sept. 2009 and under his leadership Winship completed a five-year strategic plan, a full reorganization of the senior leadership and administrative infrastructure, and an expansion of the pilot grant program to reward mentorship, inter-programmatic collaboration, innovation in clinical research, and outstanding junior investigators. Winship's 4 research programs have also undergone full re-evaluation and re-invigoration with the addition of several new program leaders and co-leaders, improved member alignment, more focused scientific themes, and greater program leader participation in cancer center decision-making and governance. Since its initial CCSG application Winship has experienced significant research growth and maturation. Total cancer-related peer-reviewed grant funding has increased 35% to $74.6 million, and NCI funding has increased 21% to $29.5 million. Currently there are 19 federally-supported multi-investigator cancer-relevant grants led by Winship members. Winship has outstanding institutional commitment, with more than $115 million in institutional support over the next five years (more than twice that committed in 2008), with its institutional status at the level of Emory's Schools of Medicine, Public Health, and Nursing. Plans are in place for an additional 57K sf of cancer research space. Patient enrollment in Winship's innovative therapeutic and non-therapeutic trials continues to increase, especially among patients from under-represented minority groups. Winship is well-positioned to leverage its growth and development as an NCI-designated cancer center into fulfilling its vision of transformative cancer research and care.

Public Health Relevance

Winship was awarded a type I CCSG in April 2009. This application represents the first competitive renewal seeking support for years 4-9. Winship is a research university-based matrix cancer center with a vision to be a transformative leader in integrating cancer research care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA138292-06S1
Application #
8791151
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2009-04-07
Project End
2017-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$74,858
Indirect Cost
$21,003
Name
Emory University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Danish, Hasan; Ferris, Matthew J; Balagamwala, Ehsan et al. (2018) Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma. Melanoma Res 28:120-125
Barwick, Benjamin G; Scharer, Christopher D; Martinez, Ryan J et al. (2018) B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation. Nat Commun 9:1900
Liu, Fakeng; Liu, Yuan; Liu, Xiuju et al. (2018) Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung Cancer 123:36-43
Kennedy, E M; Powell, D R; Li, Z et al. (2018) Galactic Cosmic Radiation Induces Persistent Epigenome Alterations Relevant to Human Lung Cancer. Sci Rep 8:6709
Xiao, Canhua; Beitler, Jonathan J; Higgins, Kristin A et al. (2018) Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer. Brain Behav Immun 74:291-295
Cassidy, Richard J; Zhang, Xinyan; Switchenko, Jeffrey M et al. (2018) Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer 124:775-784
Jhaveri, Jaymin; Chowdhary, Mudit; Zhang, Xinyan et al. (2018) Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases. J Neurosurg :1-7
Jhaveri, Jaymin; Rayfield, Lael; Liu, Yuan et al. (2018) Impact of intensity modulated radiation therapy on survival in anal cancer. J Gastrointest Oncol 9:618-630
Bilen, Mehmet Asim; Dutcher, Giselle Marie Almeida; Liu, Yuan et al. (2018) Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer 16:e563-e575
Chowdhary, Mudit; Switchenko, Jeffrey M; Press, Robert H et al. (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139:689-697

Showing the most recent 10 out of 331 publications